Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
Rhea-AI Summary
Femasys (NASDAQ: FEMY) appointed John Canning as Chief Operating Officer effective April 1, 2026. Mr. Canning brings over 25 years of medical device operations and technology leadership to support commercialization of FemBloc and FemaSeed.
The company granted a 150,000-share inducement option, vesting 25% after one year and quarterly annual vesting thereafter, approved under Nasdaq Listing Rule 5635(c)(4).
Positive
- Experienced executive with 25+ years in medical device operations
- Commercial focus to support FemBloc and FemaSeed market expansion
- Incentive alignment via 150,000-share inducement option with multi-year vesting
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
FEMY gained 11.76% with strong volume, while close peers were mixed: EKSO, LUCY, BNGO and HBIO were modestly higher and MHUA fell 27.18%. Momentum scanner names GCTK and MLSS were up but without news. This pattern points to a stock-specific reaction to Femasys’ management and equity grant news rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Board appointment | Positive | +3.5% | Added an experienced anesthesiologist and investor to support growth strategy. |
| Mar 10 | Clinical trial progress | Positive | +2.6% | Initiated enrollment in FDA-authorized FINALE pivotal trial for FemBloc. |
| Feb 26 | Regulatory certification | Positive | -1.1% | FemBloc achieved MDSAP certification to expand global regulatory and market access. |
| Feb 23 | Reimbursement milestone | Positive | +1.6% | New Category III CPT code approval for FemaSeed intratubal insemination. |
| Feb 03 | Commercial expansion | Positive | +1.4% | Signed Swiss distribution agreement expanding European footprint for core products. |
Recent news, mainly positive on clinical, commercial, and governance fronts, has usually been followed by modest positive price moves, with one notable divergence on a seemingly positive regulatory milestone.
Over the past months, Femasys has reported several milestones: European commercial expansion on Feb 3, 2026, a new CPT code for FemaSeed on Feb 23, 2026, MDSAP certification for FemBloc on Feb 26, 2026, and initiation of the FINALE pivotal trial on Mar 10, 2026. Governance changes included appointing Dr. Kenneth D. Eichenbaum to the board on Mar 18, 2026. Today’s COO appointment and inducement option fit this pattern of building operational and leadership infrastructure around an advancing women’s health portfolio.
Regulatory & Risk Context
The company has an active Form S-3 shelf registration filed on 2025-07-03 that remains effective through 2028-07-03, with at least one usage via a 424B3 filing on 2026-01-09, indicating an established mechanism for potential future capital raises.
Market Pulse Summary
This announcement adds an experienced COO with over 25 years in medical devices, plus a 150,000-share inducement option, to support commercialization of FemBloc and FemaSeed. It follows recent steps like pivotal trial initiation and European expansion, alongside 2025 sales of $2.29M and a net loss of $18.63M. Investors may watch how leadership execution, capital-raising under the active S-3, and progress in the FINALE pivotal trial translate into revenue growth and financial sustainability.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption.
Prior to joining Femasys, Mr. Canning served as Chief Operating Officer and Chief Technology Officer at Terumo Aortic, where he led global operations and technology functions, advancing the company’s endovascular product pipeline and improving operational performance. He was instrumental in Terumo’s acquisition of Bolton Medical, where he previously served as Chief Operating Officer. He began his career in manufacturing leadership roles at Medtronic Vascular, a global leader in interventional medical technologies.
“John is a skilled operator with deep expertise in scaling global MedTech organizations, advancing manufacturing excellence, and bringing innovative technologies to market,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “As we expand commercialization of our fertility and permanent birth control portfolio, including FemBloc® and FemaSeed®, John’s leadership will be instrumental in strengthening our operational capabilities, informing strategy through execution expertise, and supporting our global growth strategy.”
“Femasys has built a differentiated portfolio of transformative women’s health solutions that expand access to care in much needed areas,” said John Canning, Chief Operating Officer of Femasys. “I am excited to join the Company at this important stage of growth and for the opportunity to scale its global commercial footprint, leveraging my experience to strengthen operational execution and drive the next phase of expansion.”
Grant of Inducement Option
In connection with Mr. Canning’s appointment, Femasys has granted to Mr. Canning, effective as of his first day of employment, an option to purchase 150,000 shares of Femasys common stock at an exercise price per share equal to the closing price of Femasys common stock on the grant date as reported by Nasdaq. This grant was approved by the Compensation Committee of Femasys’ Board of Directors and made as an inducement material to Mr. Canning entering into employment with Femasys as contemplated by Nasdaq Listing Rule 5635(c)(4). The stock option will vest as to
About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment; FemSperm®, a CLIA waived sperm preparation and analysis product line; and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rate of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.1
FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is ongoing.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com
FAQ
Who is John Canning and why is his appointment important for Femasys (FEMY)?
What are the key terms of the inducement option granted to John Canning at Femasys (FEMY)?
How will John Canning’s role as COO affect Femasys’ commercialization efforts for FemBloc and FemaSeed?
When did John Canning’s employment and option grant become effective at Femasys (FEMY)?
Was the stock option grant to John Canning approved under Nasdaq rules for Femasys (FEMY)?
